1,721,259 research outputs found
Vismodegib, a small-molecule inhibitor of the Hedgehog pathway for the treatment of advanced cancers
No full textVismodegib (GDC-0449) is a small, orally administrable molecule, belonging to the 2-arylpyridine class, which was discovered by Genentech Inc under a collaboration with Curis Inc. Vismodegib inhibits the Hedgehog (Hh) pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers. Vismodegib suppresses Hh signaling by binding to and interfering with smoothened, a membrane protein that provides positive signals to the Hh signaling pathway. Preclinical studies demonstrated the antitumor activity of vismodegib in mouse models of medulloblastoma (MB) and in xenograft models of colorectal and pancreatic cancer. Phase I clinical trials in patients with advanced basal cell carcinoma (BCC) and MB highlighted an objective response to vismodegib. Reported side effects were minor, with only one grade 4 adverse event. Vismodegib is currently undergoing phase II clinical trials for the treatment of advanced BCC, metastatic colorectal cancer, ovarian cancer, MB and other solid tumors. Because of its low toxicity and specificity for the Hh pathway, this drug has potential advantages compared with conventional chemotherapy, and may also be used in combination treatments. Clinical trials with other Hh inhibitors are also ongoing and their therapeutic potential will need to be compared with vismodegib
Differential estrogen and antiestrogen responsiveness of the uterus during development in the fetal, neonatal and immature guinea pig.
No full textAfter 2-day estradiol treatments, wet weight increases in fetuses, newborns and immature guinea pigs by (means +/- SEM) 75 +/- 4%, 170 +/- 16% and 234 +/- 25%, respectively; while after 3-day tamoxifen treatments they are 83 +/- 11%, 157 +/- 35% and 127 +/- 9%, respectively. During the same periods, estradiol increases the uterine content of DNA while the effect of tamoxifen on uterine DNA decreases throughout development. Histologically, both estradiol and tamoxifen induce in the fetus an increase in the size of the stroma and myometrium. Estradiol or tamoxifen, respectively, increase the luminal epithelial cell height by (means +/- SEM) 95 +/- 2% and 67 +/- 2% in fetuses, 286 +/- 20% and 100 +/- 2% in newborns and 260 +/- 10% and 138 +/- 4% in immature animals. Luminal epithelial cell number increases in fetuses, newborns and immature animals by (means +/- SEM) 167 +/- 10%, 248 +/- 50% and 76 +/- 15%, respectively, after estradiol treatments and 160 +/- 20%, 69 +/- 15% and 17 +/- 5%, respectively, after tamoxifen treatments. Uterine epithelial growth invading the stroma was observed in both estradiol- and tamoxifen-treated fetuses. In neonatal or immature animals, estradiol increases the size and the number of endometrial glands, while tamoxifen has progressively less effects on endometrial glands and on the myometrium. It is concluded that: 1) the estradiol-induced uterotropic effect increases progressively in fetal, neonatal and immature animals; and 2) throughout development, tamoxifen has progressively weaker estrogenic properties than estradiol
Estrogen and antiestrogen effects on different lymphoid cell populations in the developing fetal thymus of guinea pig.
No full textHeterogeneity of thymic stromal cells and thymocyte differentiation: a cell culture approach.
No full textPathological and molecular heterogeneity of medulloblastoma
No full textPURPOSE OF REVIEW: The outcome of medulloblastoma patients and the quality of life of survivors can be improved by both novel therapies and a better tumor classification. This review will focus on the pathology and molecular biology of medulloblastoma and its potential to influence risk assignment and future therapy. RECENT FINDINGS: A risk stratification system of pediatric medulloblastoma based on a combination of histopathological evaluation and targeted molecular analysis can be outlined. Among the four variants recognized by the 2007 WHO classification, the desmoplastic medulloblastoma and the medulloblastoma with extensive nodularity have significantly better survival with respect to classic medulloblastoma, whereas the large-cell and anaplastic have a worse prognosis. Moreover, 17p loss, MYC amplification/expression, and 1q gain are associated with poor prognosis; in contrast, monosomy 6, mutation of CTNNB1, and trkC expression identify tumors with a favorable outcome. Emerging evidence indicates that the different precursor cell populations that form the cerebellum are susceptible to mutations in signal pathways that regulate their functions; these mutations alter normal development programmes and may result in the formation of distinct variants of medulloblastoma. SUMMARY: Better understanding of the growth control mechanisms involved in the development and progression of medulloblastoma will allow improved therapeutic stratification of patients using existing adjuvant therapy as well as the development of new therapeutic approaches
Control of stem cells and cancer stem cells by Hedgehog signaling: Pharmacologic clues from pathway dissection
No full textHedgehog is a key morphogen regulating embryonic development and tissue repair. Remarkably, when misregulated, it leads to tumorigenesis. Hedgehog signaling is triggered by binding of ligands with transmembrane receptor Ptch and is subsequently mediated by transcriptional effectors belonging to the Gli family, whose functions is tuned by a number of molecular interactions and post-synthetic modifications. The complex of these regulatory circuitries provides a tight control of developmental processes, mainly involving the modulation of genes determining the fate of stem cells. Similarly, Hedgehog regulates cancer stem cells fostering tumorigenesis. To this regard, these processes represent promising targets for novel therapeutic strategies aiming at the control of stemness reactivation and maintenance in cancer. (C) 2012 Elsevier Inc. All rights reserved
The multiple functions of Numb.
No full textNumb is an evolutionary conserved protein that plays critical roles in cell fate determination. Mammalian Numb displays a higher degree of structural complexity compared to the Drosophila homolog based on the number of encoding genes (Numb and Numb-like) and of alternative spliced isoforms. Accordingly, Numb proteins display a complex pattern of functions such as the control of asymmetric cell division and cell fate choice, endocytosis, cell adhesion, cell migration, ubiquitination of specific substrates and a number of signaling pathways (i.e. Notch, Hedgehog, p53). Recent findings indicate that, besides controlling such physiologic developmental processes, subversion of the above Numb-dependent events plays a critical role in disease (e.g. cancer). We will review here the multiple functions of mNumb and their underlying molecular mechanisms in development and disease
MicroRNAs as biomarkers for CNS cancer and other disorders
No full textThe use of miRNAs as biomarkers has gained growing interest in the last few years. Their role in regulating a great variety of targets and, as a consequence, multiple pathways, makes their use in diagnostics a powerful tool to be exploited for early detection of disease, risk assessment and prognosis and for the design of innovative therapeutic strategies. While still not fully validated, profiling of blood cells, exosomes or body fluid miRNAs would represent a tremendous and promising advance in non-invasive diagnostics of CNS disorders. A major challenge is represented by technological aspects of miRNA detection and discovery aiming to genome-wide high throughput, sensitive and accurate analysis. Although there is much to be learned in the field, this review will highlight the potential role of miRNA as a new class of biomarkers in several CNS disorders, including neurodegenerative diseases such as Alzheimer, Huntington and Parkinson diseases, schizophrenia and autism as well as different types of cancer (e.g. gliomas and medulloblastomas). (C) 2010 Elsevier B.V. All rights reserved
Cell death or survival: The complex choice of the retinoblastoma tumor suppressor protein
No full text[No abstract available
- …
